Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Acquisition Contingent Consideration Liabilities by Year
Acquisition Contingent Consideration Liabilities — Current fair value ($M) ($M)
Pfizer Acquisition Contingent Consideration Liabilities: $95M in FY2025, up 143.6% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Milestone & royalty contingent obligations from Biohaven (Nurtec/Zavzpret), Metsera, and other business combinations.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquisition Contingent Consideration Liabilities — Current fair value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 95 | +143.6% | Form 10-Q (filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 39 | -78.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 179 | +326.2% | Form 10-K (filed 2025-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 42 | -68.9% | Form 10-K (filed 2024-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 135 | +9.8% | Form 10-K (filed 2023-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 123 | -23.1% | Form 10-K (filed 2022-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 160 | -42.9% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 280 | – | Form 10-K (filed 2020-02-27) ↗ |
Breakdown
What makes up acquisition Contingent Consideration Liabilities
Cite this data
StockData. (2026). Pfizer Acquisition Contingent Consideration Liabilities ($M), annual FY2018–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/cc-liab-cur
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.